Policy· June 30, 2026 · 18 min read
China's 2026 Medical Representative Measures: Building a Compliant Model
By Ran Chen#China#NMPA#Market Access
Topic
Commercial Strategy
Launch planning, revenue forecasting, commercial operations, and strategic decision-making for biopharma products.
Biosimilars· June 1, 2026 · 12 min read
FDA biosimilar interchangeability without switching studies: the 2026 pathway
By Ran Chen#Biosimilars#Interchangeability#FDA Approval
Policy· May 22, 2026 · 11 min read
Labeling supplement timing after a new indication approval and why launch teams miss it
Policy· May 22, 2026 · 10 min read